US EditionPublished • loading... • Updated
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences secured over $50 million through oversubscribed convertible notes financing to advance its precision proteomics platform and expand leadership.
- Alamar Biosciences closed an oversubscribed convertible notes financing, bringing in more than $50 million, said Dr. Yuling Luo from Fremont, Calif.
- Alamar expanded its leadership and board to support growth, strengthening scientific stewardship as the executive leadership team and board of directors advance commercialization and operational excellence.
- Dr. Stephen Williams, MD, Ph.D., joined as Chief Scientific Officer after serving at Standard BioTools, SomaLogic, and 18 years at Pfizer; Rebecca Chambers and Dr. Frank Witney, Ph.D., joined the board.
- Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined as new investors while Illumina Ventures and Sands Capital also participated; Alamar said the investment will enable acceleration of innovation and advance commercial rollout of its precision proteomics platform.
- Company statements highlighted investor confidence and technological potential, with Dr. Yuling Luo saying, `We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners,` reflecting Alamar's focus on NULISA technology and the ARGO HT System.
Insights by Ground AI
24 Articles
24 Articles
Alamar Biosciences announces the closing of its oversubscribed convertible bond financing and the expansion of its management team
·United States
Read Full Article
Alamar Biosciences Secures Oversubscribed Funding and Expands Leadership
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina …
Coverage Details
Total News Sources24
Leaning Left4Leaning Right1Center9Last UpdatedBias Distribution64% Center
Bias Distribution
- 64% of the sources are Center
64% Center
L 29%
C 64%
Factuality
To view factuality data please Upgrade to Premium
